Literature DB >> 17064872

Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients.

M Kojima1, T Motoori, S Nakamura.   

Abstract

Lymphadenopathy, which may be associated with systemic symptoms, is frequently associated with rheumatoid arthritis (RA). Reactive non-neoplastic tissue comprises the majority of the lymph node lesions. However, several cohort studies have demonstrated that RA has an increased risk of non-Hodgkin's lymphomas (NHLs). Since the early 1990s, an atypical or malignant lymphoproliferative disorders (LPD) in patients immunosupressed with methtorexate (MTX) therapy for RA has been emphasized, namely MTX-associated LPDs. Epstein-Barr virus (EBV) has received attention in connection with the etiology of RA. The present review describes the clinicopathologic and immunohistochemical findings of reactive, atypical and malignant LPDs associated with RA along with the presence or absence of EBV in LPDs using the in situ hybridization (ISH) method. The majority of reactive lymph node lesions exhibit reactive follicular hyperplasia with interfollicular polyclonal plasmacytosis. Atypical LPDs rarely appears in RA patients. However, these cases occasionally pose difficult problems in the differential diagnosis from malignant lymphomas associated with RA or atypical and malignant LPDs showing RA-like clinicopathological findings. Clinicopathologically, three types of atypical LPDs have delineated, i.e. (i) resembling multicentric Castleman's disease (MCD); (ii) atypical paracortical hyperplasia with lymphoid follicles (APHLF) and; (iii) atypical lymphoplasmacytic immunoblastic proliferation. Malignant lymphoma associated with RA is characterized by; (i) predominance of elderly cases; (ii) usually female predominance, reflecting the sex ratio of RA; (iii) longstanding history of RA; (iv) relatively frequent advanced stage of disease; (v) majority of the patients had the B-cell phenotype; and (vi) an increased frequency of diffuse large B-cell lymphoma (DLBCL) in RA. It is unlikely that EBV is the causative agent of either reactive or atypical LPD. Among malignant lymphomas, EBV-associated lymphoma comprised only a small fraction of all NHLs in the general RA patient population.

Entities:  

Mesh:

Year:  2006        PMID: 17064872     DOI: 10.1016/j.biopha.2006.09.004

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  [How do T-cells become activated in joints?].

Authors:  M Pierer; U Wagner
Journal:  Z Rheumatol       Date:  2010-10       Impact factor: 1.372

2.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

3.  A retrospective study of 44 patients with head and neck Castleman's disease.

Authors:  Taiqin Wang; Xiaoqiang Chen; Wei Chen; Liangwen Shi; Jianzhi Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-09-04       Impact factor: 2.503

Review 4.  [Lymphadenopathy: demarcation to malignant lymphomas].

Authors:  A C Feller
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

5.  Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases.

Authors:  Dao-Ping Sun; Wen-Ming Chen; Li Wang; Zhen Wang; Jin-Hua Liang; Hua-Yuan Zhu; Lei Fan; Yu-Jie Wu; Wei Xu; Jian-Yong Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

6.  Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.

Authors:  Isabel Romero-Camarero; Xiaoyu Jiang; Yasodha Natkunam; Xiaoqing Lu; Carolina Vicente-Dueñas; Ines Gonzalez-Herrero; Teresa Flores; Juan Luis Garcia; George McNamara; Christian Kunder; Shuchun Zhao; Victor Segura; Lorena Fontan; Jose A Martínez-Climent; Francisco Javier García-Criado; Jason D Theis; Ahmet Dogan; Elena Campos-Sánchez; Michael R Green; Ash A Alizadeh; Cesar Cobaleda; Isidro Sánchez-García; Izidore S Lossos
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  A case of rheumatoid arthritis and limited systemic sclerosis overlap successfully treated with tocilizumab for arthritis and concomitant generalized lymphadenopathy and primary biliary cirrhosis.

Authors:  Eiko Saito; Shinji Sato; Shinichi Nogi; Noriko Sasaki; Naofumi Chinen; Kiri Honda; Takayuki Wakabayashi; Chiho Yamada; Naoya Nakamura; Yasuo Suzuki
Journal:  Case Rep Rheumatol       Date:  2014-04-15

Review 8.  The draining lymph node in rheumatoid arthritis: current concepts and research perspectives.

Authors:  Francesca Benaglio; Barbara Vitolo; Martina Scarabelli; Elisa Binda; Serena Bugatti; Roberto Caporali; Carlomaurizio Montecucco; Antonio Manzo
Journal:  Biomed Res Int       Date:  2015-02-22       Impact factor: 3.411

9.  Castleman disease.

Authors:  Ibrahiem Saeed-Abdul-Rahman; Ali M Al-Amri
Journal:  Korean J Hematol       Date:  2012-09-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.